Cargando…

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy

BACKGROUND: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen (HBsAg) seroclearance. Several factors have been suggested to be associated with the rate of HBsAg reduction in antiviral-naive or lamivudine therapy cohorts. However, there are few studies evaluating the factors d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xia-Xia, Li, Min-Ran, Xi, Hong-Li, Cao, Ying, Zhang, Ren-Wen, Zhang, Yu, Xu, Xiao-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831527/ https://www.ncbi.nlm.nih.gov/pubmed/27064037 http://dx.doi.org/10.4103/0366-6999.179802

Ejemplares similares

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients
por: Luo, Hao, et al.
Publicado: (2019)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017)

Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B
por: Jin, Xi, et al.
Publicado: (2012)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Effects of Entecavir on Hepatitis B Virus Covalently Closed Circular DNA in Hepatitis B e Antigen-Positive Patients with Hepatitis B
por: Shi, Ming, et al.
Publicado: (2015)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Clinical utility of entecavir for chronic hepatitis B in Chinese patients
por: Wang, Jiyao
Publicado: (2013)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study
por: Zhang, Xia-Xia, et al.
Publicado: (2016)

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
por: Li, Jun, et al.
Publicado: (2023)

240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C
por: Xu, Jing‐Hang, et al.
Publicado: (2022)

Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients
por: Lee, Jeong Guil, et al.
Publicado: (2013)

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
por: Lee, Han Ah, et al.
Publicado: (2016)

Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy
por: Lin, Tien-Ching, et al.
Publicado: (2018)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Severe Acute Hepatitis B Treated With Entecavir.
por: De Socio, Giuseppe Vittorio Luigi, et al.
Publicado: (2011)

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy
por: Cao, Weihua, et al.
Publicado: (2021)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Correlation Between Serum Entecavir Concentration and Virological Response in Patients with Chronic Type B Hepatitis
por: Wu, Zhengjie, et al.
Publicado: (2019)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)

Update on entecavir in the management of severe forms of Hepatitis B
por: Sacco, Rodolfo
Publicado: (2012)

Dupilumab in patients with chronic hepatitis B on concomitant entecavir
por: Ly, Karen, et al.
Publicado: (2019)

One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C
por: Xu, Jing-Hang, et al.
Publicado: (2022)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
por: Cho, Ju-Yeon, et al.
Publicado: (2017)

Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy
por: Lin, Tien-Ching, et al.
Publicado: (2019)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy
por: Gök Sargın, Zeynep
Publicado: (2023)

Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B
por: Perrillo, Robert, et al.
Publicado: (2013)

Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B
por: Li, Ming-Hui, et al.
Publicado: (2018)

Transient Elastography with Serum Hepatitis B Surface Antigen Enhances Liver Fibrosis Detection
por: Dai, Tianyi, et al.
Publicado: (2016)

Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion
por: Yang, Hui Y, et al.
Publicado: (2014)

Efficacy of Entecavir therapy in elderly patients with chronic hepatitis B infection
por: Tan, You-wen, et al.
Publicado: (2014)

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen– and antibody to hepatitis B core antigen–positive donor
por: Blaich, Annette, et al.
Publicado: (2012)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vpo6l0bbiphc8rbbdfescuoflk